<SEC-DOCUMENT>0001181431-11-061837.txt : 20111222
<SEC-HEADER>0001181431-11-061837.hdr.sgml : 20111222
<ACCEPTANCE-DATETIME>20111222205436
ACCESSION NUMBER:		0001181431-11-061837
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20111220
FILED AS OF DATE:		20111222
DATE AS OF CHANGE:		20111222

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Anderson Joseph
		CENTRAL INDEX KEY:			0001475259

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-176897
		FILM NUMBER:		111278833

	MAIL ADDRESS:	
		STREET 1:		38 JERMYN STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			SW1Y 6DN

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>rrd328549.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0304</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2011-12-20</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000897448</issuerCik>
        <issuerName>AMARIN CORP PLC\UK</issuerName>
        <issuerTradingSymbol>AMRN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001475259</rptOwnerCik>
            <rptOwnerName>Anderson Joseph</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O AMARIN PHARMA, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>1430 ROUTE 206, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>BEDMINSTER</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>07921</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>11683</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F5"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.03</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2020-02-10</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                    <footnoteId id="F1"/>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>120000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>120000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F3"/>
                    <footnoteId id="F5"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.</footnote>
        <footnote id="F2">As previously reported, Joseph Anderson (the &quot;Reporting Person&quot;), a partner of Abingworth LLP (&quot;ALLP&quot;), has been issued, to date, an aggregate of 11,683 ordinary shares, 50 pence par value per share (&quot;Ordinary Shares&quot;), of Amarin Corporation plc (the &quot;Issuer&quot;), in consideration of his services as a director of the Issuer. ALLP is the investment manager to a number of investment funds that include Abingworth Bioventures V L.P. (&quot;ABV V&quot;) and Abingworth Bioventures V Co-Invest Growth Equity Fund LP (&quot;AGE&quot;) (together, the &quot;Abingworth Funds&quot;).  Under an agreement entered into between ALLP and the Reporting Person on December 20, 2011, the Reporting Person is deemed to hold all of these 11,683 Ordinary Shares (collectively, the &quot;Abingworth Shares&quot;) on behalf of ALLP for the benefit of the Abingworth Funds (specifically, 5,842 Ordinary Shares are held for the benefit of ABV V and 5,841 Ordinary Shares are held for the benefit of AGE).</footnote>
        <footnote id="F3">As previously reported, the Reporting Person was granted an option on February 20, 2010, to purchase 120,000 Ordinary Shares under the Amarin Corporation plc 2002 Stock Option Plan in consideration of his services as a director of the Issuer. Under a prior agreement between the Reporting Person and ALLP, the Reporting Person was deemed to hold 103,200 of the 120,000 Ordinary Shares underlying the option for the benefit of ABV V and AGE (51,600 ordinary shares each). Pursuant to an agreement between the Reporting Person and ALLP entered into on December 20, 2011, the Reporting Person is now deemed to hold 96,000 of the 120,000 Ordinary Shares underlying the option (the &quot;Abingworth Options&quot;) for the benefit of ABV V and AGE (48,000 Ordinary Shares each) and must exercise the Abingworth Options solely upon the direction of ALLP.</footnote>
        <footnote id="F4">The stock option granted to the Reporting Person initially was scheduled to vest in four equal installments on each anniversary of the grant date (February 20, 2010). However, in light of the Issuer's announcement of favorable data relating to certain of its clinical trials, the Issuer's board of directors approved the acceleration of the vesting schedule relating to certain options (including the Reporting Person's options) granted by the Issuer, so that all of the vesting dates have been accelerated by a period of six months.</footnote>
        <footnote id="F5">ALLP, on behalf of the Abingworth Funds, is entitled to direct the disposition of the Abingworth Shares and to receive any proceeds received in connection with the sale or disposition of the Abingworth Shares, and is entitled to the Ordinary Shares issuable upon exercise of the Abingworth Options.  The Reporting Person's interest in the securities reported herein is limited to the extent of his pecuniary interest, if any, in the Abingworth Funds.  This report shall not be deemed an admission that the Reporting Person, ALLP, each Abingworth Fund or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Frederick Ahlholm, by power of attorney</signatureName>
        <signatureDate>2011-12-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
